National Research Co. (NASDAQ:NRC) President Steven D. Jackson sold 2,500 shares of the business’s stock in a transaction that occurred on Friday, September 20th. The shares were sold at an average price of $63.20, for a total value of $158,000.00.
National Research stock opened at $59.29 on Friday. The stock has a market capitalization of $1.57 billion, a PE ratio of 57.01 and a beta of 0.82. National Research Co. has a 12 month low of $35.58 and a 12 month high of $68.86. The business has a 50 day simple moving average of $58.08 and a 200-day simple moving average of $38.73. The company has a debt-to-equity ratio of 1.24, a current ratio of 0.62 and a quick ratio of 0.62.
National Research (NASDAQ:NRC) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.29 EPS for the quarter, beating the Zacks’ consensus estimate of $0.26 by $0.03. The business had revenue of $31.41 million during the quarter, compared to analysts’ expectations of $30.26 million. National Research had a return on equity of 124.11% and a net margin of 24.59%.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Monday, September 30th will be given a $0.19 dividend. This represents a $0.76 dividend on an annualized basis and a dividend yield of 1.28%. The ex-dividend date of this dividend is Friday, September 27th. National Research’s dividend payout ratio (DPR) is presently 73.08%.
Several institutional investors have recently bought and sold shares of the company. Royal Bank of Canada boosted its stake in National Research by 13.1% during the second quarter. Royal Bank of Canada now owns 15,051 shares of the company’s stock worth $866,000 after buying an additional 1,749 shares during the last quarter. Susquehanna International Group LLP acquired a new position in shares of National Research in the 2nd quarter valued at $249,000. Nuveen Asset Management LLC acquired a new position in shares of National Research in the 2nd quarter valued at $2,920,000. Citadel Advisors LLC lifted its stake in shares of National Research by 123.9% in the 2nd quarter. Citadel Advisors LLC now owns 14,718 shares of the company’s stock valued at $848,000 after purchasing an additional 8,144 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. acquired a new position in shares of National Research in the 2nd quarter valued at $228,000. Institutional investors and hedge funds own 36.03% of the company’s stock.
About National Research
National Research Corporation (NRC) is a provider of analytics and insights that facilitate revenue growth, patient, employee and customer retention and patient engagement for healthcare providers, payers and other healthcare organizations. The Company’s portfolio of subscription-based solutions provides information and analysis to healthcare organizations and payers across a range of mission-critical, constituent-related elements, including patient experience and satisfaction, community population health risks, workforce engagement, community perceptions, and physician engagement.
Featured Article: What does a hold rating mean?
Receive News & Ratings for National Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National Research and related companies with MarketBeat.com's FREE daily email newsletter.